How to buy Spruce Biosciences stock | $4.55

Spruce Biosciences Inc is a biotechnology business based in the US. Spruce Biosciences shares (SPRB) are listed on the NASDAQ and all prices are listed in US Dollars. Spruce Biosciences employs 21 staff and has a market cap (total outstanding shares value) of 0.00.

Spruce Biosciences stock price (NASDAQ: SPRB)

Use our graph to track the performance of SPRB stocks over time.

Spruce Biosciences shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$4.55
52-week range	$4.45 - $31.25
50-day moving average	$6.54
200-day moving average	$10.87
Wall St. target price	$32.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.29

Buy Spruce Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Spruce Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Spruce Biosciences price performance over time

Historical closes compared with the close of $4.55 from 2021-10-21

1 week (2021-10-15)	1.56%
1 month (2021-09-22)	-28.46%
3 months (2021-07-22)	-51.28%
6 months (2021-04-22)	-73.11%

1 year (2020-10-22)	-72.42%
2 years (2019-10-18)	N/A
3 years (2018-10-18)	N/A
5 years (2016-10-18)	N/A

Spruce Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-27.02%
Return on equity TTM	-49.65%
Profit margin	0%
Book value	$5.57
Market capitalisation	$104.7 million

TTM: trailing 12 months

Shorting Spruce Biosciences shares

There are currently 484,689 Spruce Biosciences shares held short by investors – that's known as Spruce Biosciences's "short interest". This figure is 10.5% down from 541,502 last month.

There are a few different ways that this level of interest in shorting Spruce Biosciences shares can be evaluated.

Spruce Biosciences's "short interest ratio" (SIR)

Spruce Biosciences's "short interest ratio" (SIR) is the quantity of Spruce Biosciences shares currently shorted divided by the average quantity of Spruce Biosciences shares traded daily (recently around 41747.545219638). Spruce Biosciences's SIR currently stands at 11.61. In other words for every 100,000 Spruce Biosciences shares traded daily on the market, roughly 11610 shares are currently held short.

To gain some more context, you can compare Spruce Biosciences's short interest ratio against those of similar companies.

• Insulet Corporation (PODD.US): 8.04
• Nemaura Medical (NMRD.US): 7.1
• Moderna (MRNA.US): 1.06

However Spruce Biosciences's short interest can also be evaluated against the total number of Spruce Biosciences shares, or, against the total number of tradable Spruce Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spruce Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Spruce Biosciences shares in existence, roughly 20 shares are currently held short) or 0.1164% of the tradable shares (for every 100,000 tradable Spruce Biosciences shares, roughly 116 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Spruce Biosciences.

Find out more about how you can short Spruce Biosciences stock.

Spruce Biosciences share dividends

We're not expecting Spruce Biosciences to pay a dividend over the next 12 months.

Spruce Biosciences overview

Spruce Biosciences, Inc. , a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc.

Frequently asked questions

What percentage of Spruce Biosciences is owned by insiders or institutions?
Currently 0.006% of Spruce Biosciences shares are held by insiders and 102.51% by institutions. How many people work for Spruce Biosciences?
Latest data suggests 21 work at Spruce Biosciences. When does the fiscal year end for Spruce Biosciences?
Spruce Biosciences's fiscal year ends in December. Where is Spruce Biosciences based?
Spruce Biosciences's address is: 2001 Junipero Serra Boulevard, Daly City, CA, United States, 94014 What is Spruce Biosciences's ISIN number?
Spruce Biosciences's international securities identification number is: US85209E1091